We're introducing a new look for GreyStone
Neurodegenerative diseases can be serious and life-threatening. Moreover, most of these diseases presently have no known cure. Because many neurodegenerative diseases are genetic, precision-based genetic testing can be critical to helping providers identify risk for such conditions earlier than ever before—leading to the development of treatments that can help improve symptoms, relieve pain, and increase mobility in patients.
Advances in genomic technology have produced an abundance of new information about the genetics of diseases such as Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative conditions. At GreyStone, we’re doing our part by providing patients and their care providers with access to cutting-edge, industry-defining genetic testing that can help confirm a suspected diagnosis, provide treatment guidance, support enrollment in precision therapy clinical trials, and determine whether relatives may be at risk.
Through cutting-edge genetic testing, we can help you determine a patient’s risk factors based on their DNA, so you can mitigate future consequences by taking steps now.
Neurodegenerative disorders are among the most puzzling and devastating conditions in the healthcare space. However, genetic factors are often fundamental to an understanding of neurodegenerative conditions, and so precision-based genetic testing can be instrumental in informing diagnostic and predictive approaches to these devastating diseases.
The diagnosis of a neurodegenerative condition can have implications not only for the affected individual, but also for relatives, who may be simultaneously observing the development of a loved one’s condition, and contemplating the possibility of their own at-risk status.